23andMe Investor Presentation Deck

1 2 Strong Financial Foundation to Invest in Future Growth Potential Investing in future growth potential. Integrating TeleHealth into consumer business plus increased spending on Therapeutics R&D by 34% in YTD'22 compared to the same period in the prior year Growing consumer services and genetic / phenotypic database. Balancing growth with profitability in Consumer and Research Services supports additional investment in Therapeutics' efforts 3 Strong cash position. Cash of $586 million¹ supports 23andMe's plans for significant investment in Therapeutics portfolio and strategic initiatives ¹As of December 31, 2021. Copyright © 2022 23and Me, Inc. 23andMe 50

View entire presentation